Special Issue "Current Understanding of RAD52 Functions: Fundamental and Therapeutic Insights"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 15 September 2019

Special Issue Editors

Guest Editor
Prof. Dr. Lisa Wiesmüller

Division of Gynecological Oncology, Department of Obstetrics and Gynecology of the University of Ulm, Prittwitzstrasse 43, 89075 Ulm, Germany
Website | E-Mail
Interests: DNA repair, recombination and replication, DNA damage response (DDR), DNA tolerance mechanisms, biomarkers and therapeutic strategies targeting DDR factors
Guest Editor
Dr. Vanesa Gottifredi

Fundación Instituto Leloir. Av. Patricias Argentinas 435, 1425 Buenos Aires. Argentina
Website | E-Mail
Interests: DNA repair, recombination and replication, DNA damage response (DDR), DNA tolerance mechanisms, biomarkers and therapeutic strategies targeting DDR factors

Special Issue Information

Dear colleagues,

In this Special Issue we would like to zoom into the different functions of the RAD52 helicase-like protein and the current implications of such findings for cancer treatment. Over the last few years, different laboratories have discovered particular activities of mammalian RAD52 both in the S- and M-phase that are distinct from the auxiliary role of yeast rad52 in homologous recombination. At DNA double-strand breaks, RAD52 was demonstrated to spur alternative pathways in compensating for loss of homologous recombination functions. At collapsed replication forks RAD52 activates break-induced replication. In the M-phase, RAD52 promotes the finalization of DNA replication. Its compensatory role in the resolution of DNA double-strand breaks has put RAD52 in the focus of synthetic lethal strategies, which is particularly relevant for cancer treatment.

In this Special Issue, we will gather experts in the field to convey comprehensive, insightful and current perspectives on the role of RAD52 in the maintenance of genomic integrity.

Prof. Dr. Lisa Wiesmüller
Dr. Vanesa Gottifredi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • homologous recombination
  • alternative end joining
  • break-induced replication
  • common fragile sites
  • mitotic DNA synthesis
  • synthetic lethality

Published Papers

This special issue is now open for submission.
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top